ERBB2 and neoplasm: Indeed, the BsAb comprising the intact trastuzumab IgG exhibited ADCC toward HER2-overexpressing tumor cells as effectively as parental trastuzumab, whereas the 609A scFv moiety failed to induce measurable ADCC toward T cells, even though the BsAb could effectively bind to PD1 on T cells.